Interleukin-3: Promises and Perspectives

References

• Metcalf, D. (1989). The molecular control of cell division, differentiation, commitment and maturation. Nature, 339, 27–30.
   PubMed Web of Science ®Google Scholar
• Metcalf, D. (1993). Hematopoetic regulators: Redundancy or subtlety?. Blood, 82, 3515–3523.
   PubMed Web of Science ®Google Scholar
• Ogawa, M. (1994). Hematopoiesis. J. Allergy Clin. Immunol., 94, 645–650.
   PubMed Web of Science ®Google Scholar
• Hirayama, F. and Ogawa, M. (1996). Cytokine regulation of early lymphohematopoietic development. Stem cells, 14, 369–375.
   PubMed Web of Science ®Google Scholar
• Fraser, J. K., Lill, M. C. and Figlin, R. A. (1996). The biology of cytokine sequence cascade. Seminar Oncol., 23, (Suppl 4) 2–8.
   PubMedGoogle Scholar
• Ihle, J. N. (1992). Interleukin-3 and Hematopoiesis. Chem. Immunol., 51, 65–106.
   PubMed Web of Science ®Google Scholar
• Metcalf, D., Begley, C. G., Johnson, G. R., Nicola, N. A., Lopez, A. F. and Williamson, D. J. (1986). Effects of purified bacterially synthesised murine CSF (IL3) on hematopoiesis in normal adult mice. Blood, 68, 46–57.
   PubMed Web of Science ®Google Scholar
• Anglietta, M., Sanavio, F., Stacchini, A. and Fubini, A. (1993). Interleukin 3 in vivo: Kinetic response of target cells. Blood, 82, 2054–2061.
   PubMed Web of Science ®Google Scholar
• Donahue, R. E., Sectra, J., Metzger, M., Lefebvre, D., Rock, B., Carbone, S., Nathan, D. G., Garnick, M., Sehgal, P. K., Laston, D., La Vallie, E., McCoy, J., Schendel, P. F., Norton, C., Turner, K., Yang, Y. C. and Clark, S. C. (1988). Human interleukin 3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science, 241, 1820–3.
   PubMed Web of Science ®Google Scholar
• Geissler, K., Valent, P., Bettelheim, P., Sillaber, C., Wagner, B., Kyrle, P., Hinterberger, W., Lechner, K., Leihl, E. and Mayer, P. (1992). in vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood, 79, 1155–1160.
   PubMed Web of Science ®Google Scholar
• Garnick, M. B. and O'Reilly, R. J. (1989). Clinical promise of new hematopoietic growth factors: M-CSF, IL3 and IL6. Hematol/Oncol. Clin. North. America., 3, 495–509.
   Web of Science ®Google Scholar
• Ganser, A., Lindemann, A. and Seipelt, G. (1991). Clinical effects of recombinant human interleukin 3. Am. J. Clin. Oncol., 14, suppl. 1, S51–S63.
   PubMed Web of Science ®Google Scholar
• Garland, J. M. (1986). Growth, receptors and IL3. Immunol. Today, 7, 104–105.
   PubMedGoogle Scholar
• McNiece, I. K., Langley, K. E. and Zsebo, K. M. (1991). Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp. Hematol., 19, 226–231.
   PubMed Web of Science ®Google Scholar
• Yang, Y. C. and Clark, S. C. (1989). Interleukin-3: molecular biology and biologic activities. Hematol/Oncol. Clin. North. America, 3, 441–452.
   Web of Science ®Google Scholar
• Lindmann, A. and Mertelsmann, R. (1993). Interleukin 3; structure and function. Cancer Invest., 11, 609–623.
   PubMed Web of Science ®Google Scholar
• Oster, W. and Schulz, G. (1991). IL-3: Biological and clinical effects. Intern. J. Cell Cloning, 9, 5–23.
   PubMedGoogle Scholar
• Newland, A. C. (1996). Is interleukin 3 active in anticancer drug-induced thrombocytopenia. Cancer Chemother Pharmacol., 38, (Suppl) S83–S88.
   PubMed Web of Science ®Google Scholar
• Van Gils, F. C., Westerman, Y., Visser, T. P., Burger, H., Van Leen, R. W. and Wagemaker, G. (1994). Neutralizing antibodies during treatment of homologous nonglycosylated IL-3 in rhesus monkeys. Leukemia, 8, 648–51.
   PubMed Web of Science ®Google Scholar
• Nicola, N. A. (1991). Receptor for colony stimulating factors. Br. J. Haematol., 77, 133–138.
   PubMed Web of Science ®Google Scholar
• Hara, T. and Miyajima, A. (1996). Functional and signal transduction mediated by the interleukin-3 receptor system. Stem cells, 14, 605–618.
   PubMed Web of Science ®Google Scholar
• Nicola, N. A. (1987). Why do hematopoietic growth factor receptors interact with each other? Immunol. Today, 8, 134–139.
   PubMedGoogle Scholar
• Nicola, N. A. and Metcalf, D. (1991). Subunit promiscuity among hemopoietic growth factor receptors. Cell, 67, 1–4.
   PubMed Web of Science ®Google Scholar
• Takai, S., Yamada, K., Hirayama, N., Miyajima, A. and Taniyama, T. (1994). Mapping of the human gene encoding the mutual signal-transducing subunit (beta chain) of granulocyte—macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3) and interleukin 5 (IL-5) receptor complexes to chromosome 22q13.1. Human Genetics, 93, 198–200.
   PubMed Web of Science ®Google Scholar
• Nishinkamura, R., Miyajima, A., Mee, P. J., Tybulewicz, V. L. J. and Murray, R. (1996). Hematopoiesis in mice lacking the entire GM-CSF/IL3/IL5 functions. Blood, 88, 289a.
   PubMed Web of Science ®Google Scholar
• Dirksen, U., Nishinakamura, R., Murray, R. and Burdach, S. (1996). Defective GMCSF/IL3/IL5 receptor common beta chain expression associated with human pulmonary alveolar proteinosis with or without AML and it is corrected by hematopoietic stem cell transplantation. Blood, 88, 660a.
   Web of Science ®Google Scholar
• Emerson, S. G., Yang, Y.-C, Clark, S. C. and Long, M. W. (1988). Human recombinant colony stimulating factor and interleukin 3 have overlaping but distinct functions. J. Clin. Invest., 82, 1282–1287.
   PubMed Web of Science ®Google Scholar
• Mayer, P., Valent, P., Schmidt, G., Liehl, E. and Bettleheim, P. (1989). The in vivo effects of recombinant interleukin 3: Dimonstration of basophil differentiation factor, histamine producing activity and priming of GM-CSF-responsive progenitors in non human primates. Blood, 74, 613–621.
   PubMed Web of Science ®Google Scholar
• Oster, W., Branch, M. A., Gruss, H. J., Mertelsmann, R. and Herrmann, F. (1992). IL-1 beta expression in human blood mononuclear phagocytes is differentially regulated by GM-CSF, M-CSF and IL-3. Blood, 79, 1260–1265.
   PubMed Web of Science ®Google Scholar
• Hart, P. H., Whitty, G. A., Burgess, D. R. and Hamilton, J. A. (1990). Regulation by IL-3 of human monocyte oproinflammatory mediators. Immunol., 71, 76–82.
   PubMedGoogle Scholar
• Cannistra, S. A., Vellenga, E., Groshek, P., Rambaldi, A. and Griffin, J. D. (1988). Human GM-CSF and IL-3 stimulatesmonocyte cytotoxicity through a TNF-dependent mechanism. Blood, 71, 672–676.
   PubMed Web of Science ®Google Scholar
• Hamilton, J. A. (1993). Colony stimulating factors, cytokines and monocytes macrophages-some controversies. Immunol. Today, 14, 18–23.
   PubMedGoogle Scholar
• Cohen, L., David, B. and Cavaillon, J.-M. (1991). IL-3 enhances cytokine production by LPS stimulated macrophages. Immunol. Letters, 28, 121–126.
   PubMed Web of Science ®Google Scholar
• Kurtland, J. I., Pelus, M., Ralph, P., Bockman, R. S. and Moore, M. A. S. (1979). Induction of PGE2 synthesis in normal and neoplastic macrophages. Role of colony stimulating factors distinct from effect on myeloid progenitor cell proliferation. Proc. Natl. Acad. Sci. USA, 76, 2326–2330.
   PubMed Web of Science ®Google Scholar
• Biesma, B., Pokorny, R., Kovarik, J. M., Duffy, F. A., Willemse, P. H., Mulder, N. H. and de Vries, E. G. (1993). Pharmacokinetics of human interleukin-3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Cancer Res., 53, 5915–5919.
   PubMed Web of Science ®Google Scholar
• Hovgaard, D. J., Folke, M., Mortensen, B. T. and Nissen, N. I. (1994). Recombinant human interleukin-3: pharmacokinetics after intravenous and subcutaneous bolus injection and effects on granulocyte kinetics. Br. J. Haematol., 87, 700–707.
   PubMed Web of Science ®Google Scholar
• Ceribelli, A., Fossati, C., Gamucci, T., Tritarelli, E., Testa, V., Peschle, C., Squotti, C. and Calabresi, F. (1992). Interleukin 3 by 120th continuous infusion after myelosuppressive chemotherapy: a phase 1 study. Proc. Am. Assoc. Cancer Res., 33, 231.
   Google Scholar
• Gianelli-Borradori, A. (1994). Present and future clinical relevance of interleukin 3. Stem Cells, 12, 241–252.
   Web of Science ®Google Scholar
• Skipper, H. E. (1967). Criteria associated with destruction of leukemia and solid tumors in experimental animals. Cancer Res., 27, 2636–2645.
   PubMed Web of Science ®Google Scholar
• De Vita, V. T. (1989). Principles of chemotherapy. In: Cancer principles and practice of oncology, De Vita, V.T., Hellman, S. and Rosenberg, S. A. (Eds.) pp. 276–300, JB Lippencott, Philadelphia.
   Google Scholar
• Murray, N. (1987). The importance of dose and dose intensity in lung cancer chemotherapy. Semin. Oncol., [suppl 4], 20–30.
   Google Scholar
• D'Hondt, V., Weynants, P., De Vries, E. G. E., Biesma, B., Vellenga, E., Sleijfer, D. T., Mulder, N. H., Bouma, J., Mull, R. and Willemse, P. H. B. (1992). Recombinant human interleukin 3 for chemotherapy dose intensification in advanced ovarian cancer. Proc. Am. Soc. Clin. Oncolo., 11, 4230.
   Google Scholar
• Hamblet, Y., Guillaume, T., Canon, J. L. and Beauduin, M. (1993). Dose dependent interleukin 3 stimulation of thrombopoiesis and neutropoesis in patients with small cell lung carcinoma before and following chemotherapy: a placebo controlled randomised phase Ib study. J. Clin. Oncol., 11, 2063–2071.
   PubMed Web of Science ®Google Scholar
• Dercksen, M. W., Hoekman, K., Ten Bokkel Huinink, W. W., Rakin, E. W., Dubbelman, K., Van Titeren, H., Wagstaff, J. and Pinedo, H. M. (1993). Effects of interleukin 3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. Br. J. cancer, 68, 996–1003.
   PubMed Web of Science ®Google Scholar
• Biesma, B., Willemse, P. H. B. and Mulder, N. H. (1992). Effects of interleukin 3 after chemotherapy for advanced ovarian cancer. Blood, 80, 1141–1148.
   PubMed Web of Science ®Google Scholar
• Gianni, A. M., Siena, S., Bregni, M., Di Nicola, M., Peccatori, F., Magni, M., Raragnani, F., Sklenar, I. and Bonadonna, G. (1993). Recombinant human interleukin 3 hastens trilineage hematopoietic recovery following high dose (7g/m2) cyclophosphamide cancer therapy. Ann. Oncol., 4, 759–766.
   PubMed Web of Science ®Google Scholar
• Raemakers, J., van Imhoff, G., Verdonck, L., Hessels, J. and Fibbe, W. (1993). The tolerability of continuous intravenous infusion of interleukin 3 after DHAP chemotherapy in patients with relapsed malignant lymphoma.: a phase I study. Am. J. Hematol., 67, 175–181.
   Google Scholar
• Carrington, P. A., Hill, R. J., Stenberg, P. E., Levin, J., Covash, L., Schreurs, J., Baker, G. and Levin, F. C. (1991). Multiple in-vivo effects of interleukin 3 and interleukin 6 on murine megakaryopoiesis. Blood, 77, 34.
   PubMed Web of Science ®Google Scholar
• Hoffman, R. (1993). Interleukin 3: a potential useful agent for treating chemotherapy related thrombocytopenia. J. Clin. Oncol., 4, 2057–2059.
   Google Scholar
• Newland, A. C. (1995). The problem of thrombocytopenia and its management. Anticancer Drugs, 6, 65–73.
   PubMed Web of Science ®Google Scholar
• Stahl, C. P., Winton, E. F. and Monroe, M. O. (1992). Differential effects of sequential, simultaneous and single agent interleukin 3 and granulocyte macrophage colony stimulating factors in megakaryocyte maturation and platelet response in primates. Blood, 80, 2479–2485.
   PubMed Web of Science ®Google Scholar
• Kaushansky, K., Lok, S., Holly, R. D., Broudy, V. C., Lin, N., Bailey, M. C., Forstrom, J. W., Buddie, M. M., Oort, P. J., Hagen, F. S., Roth, G. J., Papayannopoulou, T. and Foster, D. C. (1994). Promotion of megakaryocytic progenitor expansion and differentiation by the C-MPL ligand thrombopoietin. Nature, 369, 568–571.
   PubMed Web of Science ®Google Scholar
• Andrews, R. J., Winkler, A., Myerson, D., Briddell, R. A., Knitter, G. H., McNiece, I. K. and Hunt, P. (1996). Recombinant human ligant for MPL, megakaryocyte growth and development factor (MDGF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. Stem Cells, 14, 651–660.
   PubMed Web of Science ®Google Scholar
• Winton, E. F., Kim, B. K. and Srinivasiah, J. (1992). Comparative effectiveness of rh IL-6, rhIL-3 or combination of rhIL-6/IL-3 in preventing hepsulfan induced neutropenia and thrombocytopenia in a nonhuman primates. Blood, 80, 90A.
   Google Scholar
• Valant, P., Geissler, K. and Sillaber, C. (1990). Why clinician should be interested in interleukin 3. Blut., 61, 338–345.
   PubMedGoogle Scholar
• Otsuka, T., Thacker, J. D. and Hogge, D. E. (1991). The effects of IL-6 and IL-3 on early hematopoietic events in long term cultures of human marrow. Exp. Hematol., 19, 1042–1048.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Seipelt, G., Lindermann, A., Ottmann, O. G., Falk, S., Herrmann, E. M., Becher, R., Hoffken, K., Buechner, T., Klausmann, M., Frisch, J., Sculz, G., Mertelsmann, R. and Hoelzer, D. (1990). Effects of recombinant human interleukin-3 in patients with myelodysplasticsyndromes. Blood, 76, 455–462.
   PubMed Web of Science ®Google Scholar
• Willemze, R., Fenaux, P., Gerhartz, H., Zwierzina, H., de Witte, T., Stryckmans, P., Labar, B., Sklenar, I., Suciu, S., Solbu, G., Dardenne, M., Hoffbrand, V., Jacobs, A., Josten, C. and Zittoun, R. (1992). A randomized phase I/II multicenter study (EORTC 06891) of rh IL-3 in patients with myelodysplastic syndromes at relatively low risk for developing leukemia (MDS-LR). Blood, 80, 86a.
   Google Scholar
• Ganser, A., Ottmann, O. G., Seipelt, G., Lindemann, A., Hess, U., Geissler, G., Maurer A Frisch, J., Sculz, G., Mertlesmann, R. and Hoelzer, D. (1993). Effects of long term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia, 7, 696–701.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Janssen, J. W. G., Ottmann, O. G., Seipelt, G., Eder, M., Becher, R., Lindemann, A., Herrmann, A., Sculz, G., Mertelsmann, R., Hoelzer, D. and Bartram, C. R. (1991). in vivo effects of GM-CSF and IL-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorder. Leukemia, 5, 487–492.
   PubMed Web of Science ®Google Scholar
• Genthartz, H. H., Walther, J., Neuwirtova, R., Fenaux, P., Harousseau, J. L., Berksac, M., Zwierzina, H., Baumelou, E., Fiere, D., Louwagie, A., Thyss, A., Dardenne, M., Solbu, G., Suciu, S. and Zittoun, R. (1996). Randomized-3 armed phase III study of IL-3 or GM-CSF as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for a treatment of high risk myelodysplastic syndromes. Blood, 88, 580a.
   PubMed Web of Science ®Google Scholar
• Gibson, F. M., Scopes, J., Daly, S., Ball, S. E. and Gordon-Smith, E. C. (1994). In vitro response of normal and aplastic anaemia bone marrow to mast cell growth factor and in combination with GM-CSF and IL-3. Exp. Hematol., 22, 302–12.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Lindemann, A., Seipelt, G., Ottmann, O. G., Eder, M., Falk, S., Hermann, F., Kaltwasser, J. P., Meusers, P., Klausmann, M., Frisch, J., Sculz, G., Mertelsmann, R. and Hoelzer, D. (1990). Effects of recombinat IL-3 in aplastic anemia. Blood, 76, 1287–1292.
   PubMed Web of Science ®Google Scholar
• Geissler, K., Forstinger, C., Kalhs, P., Kier, P., Knoebl, P. and Lechner, K. Effects of IL-3 on responsiveness to GM-CSF in severe aplastic anaemia. Ann Intern Med., 117, 223–225.
   PubMedGoogle Scholar
• Raghavachar, A., Kaltwasser, J. P., Hermann, F., Freud, M., Ganser, A., Schrezenmaier, H., Frisch, J. and Heimpel, H. (1992). Phase I/II trials of recombinant human IL-3 and immunosuppression in refractory or relapsed aplastic anaemia. Exp. Hematol., 20, 804a.
   Web of Science ®Google Scholar
• Diamond, L., Wang, W. C. and Alter, B. P. (1976). Congenital hypoplastic aneamia. Advances in Pediatrics, 22, 349–378.
   PubMedGoogle Scholar
• McGuckin, C. P., Uhr, M. R. and Gordon-Smith, E. C. (1995). Diamond Blackfan anaemia: three patterns of in vitro response to hemopoietic growth factors. Br. J. Haematol., 89, 457–464.
   PubMed Web of Science ®Google Scholar
• McGuckin, C. P., Uhr, M. R., Ball, S. E., Gordon-Smith, E. C. (1996). In vitro progenitor analysis in a Diamond Blackfan anaemia patient who responded once but not twice to IL-3 therapy, using short term and long term culture and c-kit analysis. Br. J. Haematol., 93, 319–325.
   PubMed Web of Science ®Google Scholar
• Ball, S. E., Tchernia, G., Wranne, L., Bastion, Y., Bekassy, N. A., Bordigoni, P., Debre, M., Ellinder, G., Kamps, W. A., Lanning, M., Leblanc, T. and Makipernaa, (1995). Is there role of IL-3 in Diamond Blackfan Anaemia. Br. J. Haematol., 91, 313–318.
   PubMed Web of Science ®Google Scholar
• Dunbar, C. E., Smith, D., Kimball, J., Garrison, L., Nienhuis, A. W. and Young, N. S. (1991). Treatment of Diamond Blackfan anaemia with haematopoietic-growth factors, GM-CSF and IL-3: sustained remission following IL-3. Br. J. Haematol., 79, 316–321.
   PubMed Web of Science ®Google Scholar
• Gillo, A. P., Faulkner, L. B., Alter, B. P., Reilly, L., Klafter, R., Heller, G., Young, D. C., Lipton, J. M., Moore, M. A. S., O'Reilly, R. J. (1993). Treatment of Diamond-Blackfan Anemia with recombinant human interleukin-3. Blood, 82, 744–751.
   PubMed Web of Science ®Google Scholar
• Freedman, M. H. (1993). Erythropoiesis in Diamond-Blackfan anemia and the role of interleukin-3 and Steel factor. Stem Cells, 11, 98–104.
   PubMed Web of Science ®Google Scholar
• Guillaume, T., D'Hondt, V. and Symann, M. (1993). IL-3 and peripheral blood stem cell harvesting. Stem Cells, 11, 173–181.
   PubMed Web of Science ®Google Scholar
• Vose, J. M., Kessinger, A., Bierman, P. J., Sharp, G., Garrison, L. and Armitage, J. O. (1992). The use of rhIL-3 for mobilization of peripheral blood stem cells in previously treated patients with lymphoid malignancies. Int. J. Cell Cloning, 10, 62–64.
   Google Scholar
• Heinzinger, M., Waller, C., Scheid, S., Mertelsmann, and Lange, W. (1996). Quality of IL-3 and G-CSF mobilizedstem cells in patients with early chronic phase CML. Blood, 88, 585a.
   Web of Science ®Google Scholar
• Hockner, P., Giessler, K., Kurz, M., Wagner, A. and Gerhatl, K. (1993). Potentiation of GM-CSF or G-CSF induced mobilization of circulating progenitor cells by pretreatment with IL-3 and harvest by apheresis. International J. Artificial organs, 16 S-5, 25–29.
   Web of Science ®Google Scholar
• Brugger, W., Bross, K., Frischi, J., Dern, P., Weber, B., Mertelsmann, R. and Kanz, L. (1992). Mobilisation of peripheral blood progenitor cells by sequential administration of interleukin 3 and granulocyte monocyte colony stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplantin. Blood, 79, 1193–1200.
   PubMed Web of Science ®Google Scholar
• Brugger, W., Frisch, J., Schulz, G., Pressler, K., Mertelsmann, R. and Kanz, L. (1992). Sequential administration of IL-3 and GM-CSF following standard dose combination chemotherapy with Etoposide, Ifosfamide and cisplatin. J. Clin. Oncol., 10, 1452–1459.
   PubMed Web of Science ®Google Scholar
• Naparstek, E., Harden, Y., Ben-Shahar, M., Nagler, A., Mumcuoglu, M., Weirs, L., Samuel, S. and Slavin, S. (1992). Enhanced marrow recovery by short preincubation of marrow allograft with human recombinant IL-3 and GM-CSF. Blood, 80, 1673–1678.
   PubMed Web of Science ®Google Scholar
• Crump, M., Couture, F., Kovacs, M., Saragosa, R., McCrae, J., Brandwein, J., Huebsch, L., Baeuregard-Zollinger., and Keating, A. (1993). Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Exp. Hematol, 21, 405–410.
   PubMed Web of Science ®Google Scholar
• Neumunaitis, J., Appelbaum, F. R. and Singer, J. W. (1993). Phase I trial with recombinant human interleukin 3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood, 82, 3273–3278.
   PubMed Web of Science ®Google Scholar
• Fay, J. W., Lazarus, H., Herzig, R., Saez, R., Stevens, D. A., Collins, R. A., Pineiro, L. A., Cooper, B. W., DiCesare, J., Campion, M., Fesler, J. M., Herzig, G. and Bernstein, S. H. (1994). Sequential administration of human IL-3 and granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for maligant lymphoma: A phaser I/II multicentre study. Blood, 84, 2151–2157.
   PubMed Web of Science ®Google Scholar
• Sheridan, W. P., Begley, C. G., Jutkner, C. A., Szer, J., To, B. L., Maher, D., McGrath, K. M., Morstyn, G. and Fox, R. M. (1992). Effects of peripheral blood progenitor cells mobilised by Filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet, 339, 640–644.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj, S., Broxmeyer, H. E., Andreef, M., Banders, J. C., Buescher, S. E., Benjamin, R. S., Papadopoulos, N. E., Burgess, A., Patel, S., Plager, C., Hittelman, W. N., McAlister, I., Garrison, L. and Williams, D. E. (1995). In vivo biological effects of PIXY 321, a synthetic hybrid protein of recombinant GM-CSF and IL-3 in cancer patients with normal hematopoiesis. A phase I study. Blood, 86, 2098–2105.
   PubMed Web of Science ®Google Scholar
• Ellis, G. K., Hutchins, L., Limenez-Martin, M., Pecora, A. L., Barnadas, A., Meisenberg, B., Nabholtz, J. M., Cortes-Funes, H., Rifkin, R., Chang, A. Y. C., Garrison, L., George, C. and Giles, F. C. (1996). Phase III double blind study of PIXY321 vs G-CSF after CEP for breast or ovarian carcinoma. Blood, 88, 449a.
   Web of Science ®Google Scholar
• Steinman, R. M. (1991). The dendritic cell system and its role in immunogenecity. Ann. Rev. Immunol., 9, 271–296.
   PubMed Web of Science ®Google Scholar
• Caux, C., Vanbervliet, B., Massacrier, C., Durand, I. and Banchereau, J. (1996). Interleukin 3 cooperates with tumor necrosis factor alpha for the development of human dendritic/langerhans cells from cord blood CD34+ hematopoietic progenitor cells. Blood, 87, 2376–2385.
   PubMed Web of Science ®Google Scholar
• Nair, S. K., Boczkowski, D., Snyder, D. and Gilboa, E. (1997). Antigen presenting cells pulsed with unfractionated tumor-drived peptides are potent tumor vaccines. EM. J. Immunol., 27, 589–597.
   Web of Science ®Google Scholar
• Girolomoni, G. and Ricciardi-Castagnoli, P. (1997). Dendritic cells hold promise for immunotherapy. Immunol. Today, 18, 102–104.
   PubMedGoogle Scholar
• Williams, S. F., Lee, W. J., Bender, J. G., Zimmerman, T., Swinney, P., Blake, M., Carreon, J., Schilling, M., Smith, S., Williams, D. E., Oldham, F. and Van Epps, D. (1996). Selection and expansion of peripheral blood CD34+cells transplantation for breast cancer. Blood, 87, 1687–1691.
   PubMed Web of Science ®Google Scholar
• Steen, R., Morkrid, L., Tjonnfjord, G. E. and Egeland, T. (1994). c-kit ligand combined with GM-CSF and or IL-3 can expand CD34+ hematopoietic progenitor subsets for several weeks in vitro. Stem Cells, 12, 214–24.
   PubMed Web of Science ®Google Scholar
• Serrano, F., Varas, F., Bernad, A. and Bueren, J. A. (1994). Accelerated and long-term hematopoietic engraftment in mice transplanted with ex-vivo expanded bone marrow. Bone Marrow Transplant, 14, 855–62.
   PubMed Web of Science ®Google Scholar
• Peters, S. O., Vergilis, K. L., Habibian, H. K. and Quesenberry, P. J. (1996). Culture of murine hematopoietic progenitor cells cultured with IL-3, IL-6, IL-1 and SCF for 48 hours leads to expansion of short term repopulating cells but impairs long-term engraftment. Blood, 88, 595a.
   Web of Science ®Google Scholar
• Adelmann, M., Schulze, D., Osten, C. V., Pfeffekorn, L., Beyer, C., Emmerich, B. and Starka, C. (1996). Ex-vivo Blood stem cell expansion in liquid culture with cytokine cocktails. Role of thrombopoietin. Blood, 88, 604a.
   Web of Science ®Google Scholar
• Huang, S., Peterson, S., Li, X., Young, D., Wong-Staal, F. and Law, P. and Ho A. D. Gene transduction of human CD34+ CD38-, HLA-DR+ hematopoietic stem cell/progenitor cells. Blood, 88, 429a.
   PubMedGoogle Scholar
• Doa, M. A. and Nolta, J. A. (1996). Inclusion of IL-3 during retroviral-mediated transduction on stromal support does not increase the extent of gene transfer into long term engrafting human hematopoietic progenitors. Blood, 88, 428a.
   Web of Science ®Google Scholar
• Billiau, A. and Vandekerckhove, F. (1991). Cytokines and their interaction with other inflammatory mediators in the pathogenesis of sepsis and septicshock. EM. J. Clin. Investigators, 21, 559–573.
   Web of Science ®Google Scholar
• Shoenfeld, Y. and Fishman, P. (1994). Role of IL-3 in the antiphospholipid syndrome. Lupus, 3, 259–261.
   PubMed Web of Science ®Google Scholar
• Petri, M. (1997). Pathogenesis and treatment of antiphospholipid syndrome. Med. Clin. North America, 81, 151–177.
   PubMed Web of Science ®Google Scholar
• Welsch, S. and Branch, D. W. (1997). Antiphospholipid syndrome in pregnancy. Obstetric concerns and treatment. Rheum. Dis. Clin. North. Am., 23, 71–84.
   PubMed Web of Science ®Google Scholar
• Fishman, P., Falach-Vaknine, E., Zigelman, R., Bakimer, R., Sredni, B., Djaldetti, M. and Shoenfeld, Y. (1993). Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant IL-3. J. Clin. Invest., 91, 1834–1837.
   PubMed Web of Science ®Google Scholar
• Fishman, P., Shoenfeld, Y., Hart, J., Zigelman, R., Shamir, Y., Feldberg, D., Inhar, O., Sredni, D. and Djaldetti, M. (1992). Interleukin-3 like activity levels in pregnant women: possible modulation by progesterone. J. Reprod. Immunol., 22, 211–216.
   PubMed Web of Science ®Google Scholar